Here’s Why Cencora (COR) Shares Rose 8% in Q4

1 day ago 2

Soumya Eswaran

Fri, March 20, 2026 astatine 8:25 AM CDT 3 min read

TimesSquare Capital Management, an equity concern absorption company, released its “U.S. Focus Growth Strategy” fourth-quarter 2025 capitalist letter. A transcript of the missive tin be downloaded here. The strategy returned -3.55% (gross) and -3.76% (net) successful the 4th fourth compared to a -3.70% instrumentality for the Russell Midcap Growth Index. In 2025, the strategy returned 14.84% (gross) and 13.88% (net) compared to 8.66% for the index. Global equity markets ended the 4th connected a affirmative note, with Europe leading, followed by Emerging Markets. In astir markets, ample caps outperformed tiny caps. The commercialized truce betwixt the United States and China was prolonged for an further year, but planetary geopolitical concerns, whether related to tariffs oregon not, persisted. Third-quarter GDP exceeded expectations, but user caution persists owed to ongoing labor-market softening, influencing the Fed’s determination connected involvement complaint cuts. Please reappraisal the Strategy’s apical 5 holdings to summation insights into their cardinal selections for 2025.

In its fourth-quarter 2025 capitalist letter, TimesSquare Capital U.S. Focus Growth Strategy highlighted Cencora, Inc. (NYSE:COR). Cencora, Inc. (NYSE:COR) is an American institution that sources and distributes pharmaceutical products. On March 19, 2026, Cencora, Inc. (NYSE:COR) banal closed astatine $331.74 per share. One-month instrumentality of Cencora, Inc. (NYSE:COR) was -8.13%, and its shares gained 24.05% implicit the past 52 weeks. Cencora, Inc. (NYSE:COR) has a marketplace capitalization of $64.534 billion.

TimesSquare Capital U.S. Focus Growth Strategy stated the pursuing regarding Cencora, Inc. (NYSE:COR) successful its 4th fourth 2025 capitalist letter:

"Our preferred Health Care stocks are companies that supply caller therapies for unmet needs and bid premium pricing, oregon specialized work providers. Cencora, Inc. (NYSE:COR), a pharmaceutical sourcing and organisation company, gained 8%. Fiscal fourth-quarter net outpaced statement estimates, with spot successful the U.S. offsetting a miss successful planetary business. Management besides announced that it is considering strategical alternatives for the carnal wellness and non-core parts of its PharmaLex business."

Protagenic & Phytanix Merge successful All-Stock Move, Sparking Retail Frenzy

Cencora, Inc. (NYSE:COR) is not connected our database of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 61 hedge money portfolios held Cencora, Inc. (NYSE:COR) astatine the extremity of the 4th quarter, up from 59 successful the erstwhile quarter. In the archetypal 4th of fiscal 2026, Cencora, Inc.'s (NYSE:COR) consolidated gross accrued 5.5% year-over-year to $85.9 cardinal owed to coagulated maturation successful some reportable segments. While we admit the imaginable of Cencora, Inc. (NYSE:COR) arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

Read Entire Article